Indoco Remedies Reports Q2 FY26 Earnings Uptick; USFDA & European Business Updates
Indoco Remedies released its Q2 FY26 earnings call transcript, reporting revenue growth, 0 USFDA observations for its API plant, and ANDA approval for Rivaroxaban. Management expects improved performance and double-digit growth in Europe.
The announcement is highly impactful as it covers Q2 FY26 financial results, provides crucial updates on U.S. FDA inspections and approvals, outlines strategic shifts in international business, addresses debt management, and offers a forward-looking revenue target and margin expectations, all of which significantly affect investor sentiment and future valuations.
The announcement conveys a positive outlook, highlighting an 'uptick in performance' after a difficult period, successful U.S. FDA inspection with zero observations for the API facility, ANDA approval, and management's confidence in future growth, margin improvement, and debt reduction.
Indoco Remedies Limited released the transcript of its Earnings Conference Call held on 6 November 2025, discussing the unaudited standalone and consolidated financial results for the Quarter and Half Year Ended 30 September 2025. Key highlights from the announcement include: Financial Performance (Q2 FY26): Consolidated net revenues grew 9.6% year-on-year to ₹471.8 crore, while standalone net revenues increased 8.8% to ₹429.3 crore. Consolidated EBITDA stood at ₹43.1 crore (9.1% of sales), and standalone EBITDA was ₹53.4 crore (12.4% of sales). Domestic Business: India business saw strong performance in anti-infective and respiratory segments, with brands like ATM, Febrex Plus, and Karvol Plus. The company launched 6 new products, including Vepazil, Tuspel AA, Braceness, Multi Fibro, and Toco Fibro capsules. International Business & Regulatory: The U.S. FDA successfully inspected the API manufacturing facility at Patalganga with 0 observations. The company received final ANDA approval from the U.S. FDA for Rivaroxaban tablets. Management noted an uptick in performance for Q2 FY26 after a challenging H2 last year due to supply issues. Europe & US Operations: The Master Manufacturing Plant (MMP) in Europe is completed, with expectations of double-digit growth and improved EBITDA returns from Q3. For the U.S. market, Indoco Remedies is ready for a U.S. FDA audit for Goa Plant 2 and has received acknowledgment. The company is exploring CMOs for derisking product supplies. Debt & Strategy: The company has made significant capex investments in the last two years, but no further major capex is planned. Management aims to reduce R&D spend and expects improved cash flow to repay loans, targeting ₹52 crore in H2 FY26 and ₹140 crore in FY27. The company is transitioning to a front-ending model in regulated markets and investing in the Indian OTC business. Outlook: The management anticipates a delay of approximately 18 months for the ₹5,000 crore revenue target beyond 2027, but is confident of reaching around ₹3,500 crore in the next three years with substantial margin improvement.
What to do with a filing like this
Indoco Remedies Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indoco Remedies Limited. Read the original for the full detail.